AL Amyloidosis

View All

AL Amyloidosis Therapeutics Market Outlook
Assessing How Emerging Therapies Will Transform the AL Amyloidosis Treatment Dynamics

AL Amyloidosis is a rare disease, with around 8,500 new cases diagnosed each year in the 7MM. This disease mostly affects elderly persons median age of 64, with slight male predominance (54%). As per our estimates, the highest AL Amyloidosis incidence was observed in the US in 2021. Moreover, there are more than 30...

Find More

Another Failed NASH Drug; Takeda’s Dengue Shot; Innovent’s Cholangiocarcinoma Clinical Trial; TLX66 in AL Amyloidosis
TLX66 in AL Amyloidosis; Takeda’s Dengue Shot; Innovent’s Cholangiocarcinoma Clinical Trial; Another Failed NASH Drug

TLX66 Meets Study Objectives, Holding Out in AL Amyloidosis Telix Pharmaceuticals reported the results from the TRALA trial (Targeted Radiotherapy for AL Amyloidosis), a Phase I/IIa trial evaluating the safety and toxicity of TLX66 as the sole bone marrow conditioning agent prior to autologous hematopoietic stem...

Find More